Ied of gist (remember, this is mostly pre-imatinib! ) and apparently the remaining 12% are alive on imatinib (prescribed after recurrence). no prescription viagra They found that tumor size was much less predictive of outcome than the mitotic count. Only 12% of patients with a mitotic count over 10/50 hpf remained disease-free after surgery, and all patients with a mitotic count over 20/50 hpf experienced recurrence. Some slow-growing tumorsâ canâ reach large sizes without becoming aggressive. Bearzi et al describe two cases in point: an 11-cm gastric gist with a mitotic count of zero was removed and had not recurred after five years. A 14-cm small intestinal tumor that had infiltrated the bladder, with a mitotic count of 3/50 hpf, had not recurred in five years after resection of all tumor and the affected part of the bladder. Data such as these can indicate which patients may benefit most from adjuvant imatinib after successful surgery, to prevent recurrence. Because the swedish studies used the ki-67 index (not mitotic rate) as the measure of tumor cell proliferation, it is not possible to make a direct comparison from the bearzi et al study to the swedish dataset. However, nilsson et al (2005) did show the following: if you hold tumor size equal, then risk increases as the ki-67 proliferation index increases. If you hold ki-67 proliferation index constant, then risk increases as tumor size increases. Examination of the graphs illustrating the preceding statements in the nilsson et al paper shows that there is a wider divergence in survival as a function of proliferation index than there is for tumor size. For example, the prediction curv.     Nursing Tops

    Maternity Dresses

    Nursing Dresses

    Nursing Pajamas

    Nursing Bras

    Nursing Accessories 

    Post-Pregnancy

    Kool Kids Stuff

    Gift Certificates

    End of Line Clearance